Skip to content
AnalystLens

Charles River Laboratories International 8-K/A Report, Executive Changes (Sep 19, 2025)

Reports
Leadership Changes
Filing Date
Filed September 19, 2025
Period End
September 12, 2025
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Jan ’22Jan ’22
  4. Leadership change8-K · Jan ’24Jan ’24

Summary

Summary of the 8-K/A filed September 19, 2025. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. filed this Form 8-K/A on September 19, 2025, to amend its Form 8-K filed on September 16, 2025.

The original report disclosed the resignation of Flavia H. Pease as Corporate Executive Vice President and Chief Financial Officer, and the appointment of Michael G. Knell as interim Chief Financial Officer.

This amendment supplies compensation details for Mr. Knell that had not been determined when the original report was filed. The Compensation Committee of the Company's Board of Directors approved the compensation changes on September 15, 2025, in connection with Mr. Knell's appointment as interim Chief Financial Officer and interim principal financial officer. The package includes an increase in annual base salary to $500,000,a effective September 28, 2025; a $10,000 monthly cash payment during his term as interim Chief Financial Officer, effective October 1, 2025; and a one-time grant of restricted stock units with a grant value of $500,000.

The restricted stock units are to be granted on November 6, 2025, the first business day after the press release on third-quarter 2025 financial results. Half vest on the first anniversary of the grant date and half on the second anniversary.

The filing is signed by Matthew L. Daniel, Corporate Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer.

Key Highlights

  1. Flavia H. Pease resigned as Corporate Executive Vice President and Chief Financial Officer, and Michael G. Knell was appointed interim Chief Financial Officer and interim principal financial officer.
  2. This 8-K/A discloses compensation details for Mr. Knell that were not determined when the original September 16, 2025 Form 8-K was filed.
  3. The Compensation Committee approved on September 15, 2025 an increase in Mr. Knell's annual base salary to $500,000, effective September 28, 2025.
  4. Mr. Knell will receive a $10,000 monthly cash payment during his interim service as Chief Financial Officer, effective October 1, 2025.
  5. A one-time restricted stock unit grant with a grant value of $500,000 is scheduled for November 6, 2025, the first business day after the third-quarter 2025 financial results press release.
  6. The restricted stock units vest 50% on the first anniversary of the grant date and the remaining 50% on the second anniversary.

Frequently Asked Questions

  1. Who is leading the finance function at Charles River Laboratories following the CFO change?

    Michael G. Knell has been appointed interim Chief Financial Officer and interim principal financial officer, succeeding Flavia H. Pease, who resigned from the role.

  2. What is Mr. Knell's base salary as interim CFO?

    The Compensation Committee approved an increase in his annual base salary to $500,000, effective September 28, 2025.

  3. What additional cash compensation does Mr. Knell receive for serving as interim CFO?

    He will receive a $10,000 monthly cash payment during his term of service as interim Chief Financial Officer, effective October 1, 2025.

  4. When and how will Mr. Knell's equity award vest?

    He will receive a one-time grant of restricted stock units with a grant value of $500,000 on November 6, 2025. Half vests on the first anniversary of the grant date and half on the second anniversary.

  5. Why was this 8-K/A filed?

    The company filed this amendment to disclose details of Mr. Knell's compensation that had not been determined at the time of the original September 16, 2025 Form 8-K.